医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

OKI and Mipsology of France Enter Japanese Market for FPGA-Based Machine Learning (ML) Development Support Services

2020年11月10日 PM02:00
このエントリーをはてなブックマークに追加


 

TOKYO

OKI IDS Co., Ltd. (OIDS; president: Satoshi Shimizu; head office: Takasaki, Gunma Prefecture), an OKI Group company providing firmware and hardware design and development services, has teamed with Mipsology SAS (CEO: Ludovic Larzul; head office: France), the company providing the Zebra neural network machine learning accelerating software for use with FPGAs.*1 The partners today announced the signing of a technical partnership agreement on October 20, 2020, with the stated goal of entering the domestic Japanese high-speed ML-based image processing market. This agreement marks the launch of a design and development service intended to support faster ML processing based on FPGA technology in domestic Japanese markets for applications requiring high-speed image processing, including autonomous driving, remotely controlled robots, telemedicine, and video monitoring.

While ML developments to date have centered on CPUs/GPUs, ML applications that require real-time capabilities are driving demand for faster processing. FPGAs are devices capable of performing complex arithmetic processing in parallel for high-speed processing of large data volumes. Running ML programs on FPGAs allows processing six times faster or better (the ratio for current OIDS ML programs).

The agreement will enable both companies to offer services that accelerate ML processing by running ML programs on FPGAs. OIDS installs and optimizes client ML programs running on FPGAs using Mipsology’s Zebra platform to meet customer performance requirements with short lead times. OIDS offers FPGA intellectual property (IP) design and development services related to high-speed image transmission and communications processing, primarily in Japan, while Mipsology offers acceleration platforms for ML processing, primarily in Europe and in the US. The partnership will seek to expand ML development support services by meeting the demand for faster ML, a market sector expected to see significant future growth in Japan.

Xilinx, the world leader in FPGAs, and Avnet, a global provider of technology solutions centering on Xilinx, commented as follows in response to this announcement.

“We’re delighted to learn about the technical partnership between OIDS, a premium design service partner of Xilinx, and Mipsology, our ML acceleration partner for Alveo accelerator cards.*2 Working together we look forward to expanding access to and use of edge AI*3 devices utilizing our FPGAs and Alveo cards across a wide range of industries.”

Hiroshi Hayashida
Japan Country Lead
Xilinx K.K.

“We’re confident the development solutions proposed by OIDS, backed by its extensive experience with high-speed image processing and vision interface design,*4 together with Mipsology’s Zebra high-performance ML engine, will provide essential solutions in the development of ultra-low-latency processing systems for customers.”

Yasumoto Mogi
Regional President, Avnet Japan

[Mipsology overview]
Corporate name: Mipsology SAS
Founded: 2015
Employees: 45
CEO: Ludovic Larzul
Location: Palaiseau, France
Business activities: Mipsology is an innovative startup focusing on state-of-the-art DNN*5 inference acceleration. Its Zebra software platform represents market-leading technology enabling neural network inference acceleration on FPGAs and ML development without being aware of underlying hardware technology. The company is composed of engineers and scientists who have created world-leading FPGA-based supercomputers over the past 20 years.

[OIDS overview]
Corporate name: OKI IDS Co., Ltd.

Founded: March 10, 2014
Capital: JPY50 million
Employees: 78
President & CEO: Satoshi Shimizu
Location: Takasaki, Gunma Prefecture
Business activities: Development, sales, and consulting for video/audio/communications firmware and hardware, development, sales, and consulting for high-speed data transmission hardware; product development of industrial and medical equipment

Terminology
*1: FPGA (field-programmable gate array)
FPGAs are programmable logic devices/integrated circuits that can be configured by the customer or designer after manufacture.

*2: Alveo accelerator card
Alveo accelerator cards incorporate Xilinx FPGAs for performance acceleration for DNN inference and other applications.

*3: Edge AI
Edge AI is AI designed to run locally, at actual sites. By eliminating the need for communication, compared to traditional cloud-based ML, this offers superior real-time performance, lower power consumption, and reduced size.

*4: Vision interface
The term vision interface refers to hardware that captures and transfers video signals via cable to a PC or other device.

*5: DNN (deep neural network)
DNNs are artificial neural networks designed to implement deep learning algorithms modeling human/animal cognition based on a multi-layer structure.

Notes:
- Oki Electric Industry Co., Ltd. is commonly referred to simply as “OKI.”
- Mipsology and Zebra are registered trademarks in the US.

- Corporate names and product names contained in this document are the trademarks or registered trademarks of the respective companies.

View source version on businesswire.com: https://www.businesswire.com/news/home/20201109005415/en/

CONTACT

Press Contact:

Oki Electric Industry Co., Ltd.

Public Relations Division

Contact form

Customer Contact:

OKI IDS Co., Ltd.

Sales & System Engineering Department, Business division

Phone: +81-27-324-2139

Contact form

Mipsology

Business Development, Japan & Asia

Tsugumi Fujitani

Contact form

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Sherlock Biosciences Strengthens Intellectual Property Portfolio in CRISPR-based Diagnostics Through Exclusive License Agreement with Tolo Biotech
  • New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
  • Shape Therapeutics推出AAVid™衣壳发现平台和新型组织特异性AAV变异识别,解决基因治疗根本性的投药挑战
  • 三叶草生物发布其“S-三聚体”重组亚单位新冠候选疫苗 I 期临床研究积极结果
  • Clover Biopharmaceuticals Announces Positive Phase 1 Data for its Adjuvanted S-Trimer COVID-19 Vaccine Candidates